<div id="readability-page-1"><p>K.J. Harrison &amp; Partners Inc bought a new stake in shares of  Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities &amp; Exchange Commission. The institutional investor  bought 2,001 shares of the biopharmaceutical company's stock, valued at approximately $1,051,000.</p><ul><li>Big Dippers: 3 Stocks Near 1-Year Lows That Could Surge in 2025</li></ul><p>Several other institutional investors and hedge funds have also added to or reduced their stakes in REGN. PGGM Investments increased its stake in shares of  Regeneron Pharmaceuticals by 159.7% during the 2nd quarter. PGGM Investments now owns 84,397 shares of the biopharmaceutical company's stock worth $44,308,000 after purchasing an additional 51,900 shares during the last quarter.  Founders Capital Management LLC grew its stake in  Regeneron Pharmaceuticals by 7.0% in the 2nd quarter. Founders Capital Management LLC now owns 8,274 shares of the biopharmaceutical company's stock valued at $4,344,000 after buying an additional 538 shares during the last quarter.  Sepio Capital LP grew its stake in  Regeneron Pharmaceuticals by 33.1% in the 1st quarter. Sepio Capital LP now owns 3,389 shares of the biopharmaceutical company's stock valued at $2,150,000 after buying an additional 842 shares during the last quarter.  China Universal Asset Management Co. Ltd. grew its stake in  Regeneron Pharmaceuticals by 3.9% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 25,629 shares of the biopharmaceutical company's stock valued at $16,255,000 after buying an additional 955 shares during the last quarter.  Finally, Generate Investment Management Ltd acquired a new position in  Regeneron Pharmaceuticals in the 2nd quarter valued at $6,300,000. 83.31% of the stock is owned by institutional investors and hedge funds. </p><h2>Regeneron Pharmaceuticals Price Performance</h2><p>NASDAQ:REGN opened at $651.80 on Monday. The company has a 50-day moving average of $581.80 and a 200-day moving average of $565.38. The company has a market capitalization of $69.08 billion, a price-to-earnings ratio of 15.61, a PEG ratio of 2.03 and a beta of 0.31. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $883.15. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.06. </p><ul><li>Best Biotech Stocks to Buy in 2025</li></ul><p>Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, topping analysts' consensus estimates of $9.73 by $2.10. The company had revenue of $3.75 billion during the quarter, compared to the consensus estimate of $3.57 billion. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The firm's revenue for the quarter was up .9% compared to the same quarter last year. During the same period last year, the firm earned $12.46 EPS.  As a group, equities research analysts anticipate that  Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year. </p><h2>Regeneron Pharmaceuticals Dividend Announcement</h2><p>The company also recently declared a quarterly dividend, which will be paid on Friday, December 5th. Investors of record on Thursday, November 20th will be issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend is Thursday, November 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 8.43%. </p><h2>Analysts Set New Price Targets</h2><ul><li>3 Stocks With Ironclad Balance Sheets for Long-Term Stability</li></ul><p>REGN has been the topic of a number of research analyst reports. Weiss Ratings  reiterated a &#34;hold (c-)&#34; rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 8th. Cantor Fitzgerald raised their target price on shares of Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the company an &#34;overweight&#34; rating in a research note on Wednesday, October 29th. Redburn Atlantic upgraded shares of Regeneron Pharmaceuticals to a &#34;strong-buy&#34; rating in a research note on Thursday, August 14th. Guggenheim increased their price target on shares of Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the company a &#34;buy&#34; rating in a report on Wednesday, October 29th. Finally, Royal Bank Of Canada increased their price target on shares of Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the company a &#34;sector perform&#34; rating in a report on Wednesday, October 29th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned  a Buy rating, seven have assigned  a Hold rating and one  has issued  a Sell rating to the stock. According to data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $802.36.</p><p><b>Check Out Our Latest Research Report on REGN</b></p><h2>Insider Transactions at Regeneron Pharmaceuticals</h2><p>In related news, Director Christine A. Poon sold 6,500 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the completion of the transaction, the director directly owned 2,352 shares of the company's stock, valued at $1,538,843.04. This trade represents a 73.43% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 7.02% of the stock is owned by corporate insiders. </p><h2>About Regeneron Pharmaceuticals</h2> (Free Report)<p>Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.</p><h2>See Also</h2><ul><li>Five stocks we like better than Regeneron Pharmaceuticals</li><li>Biggest Stock Losers - Today’s Biggest Percentage Decliners</li><li>3 Safe and Steady Stocks for Any Market</li><li>What is a support level?</li><li>Is Lemonade Stock Set for a Big Squeeze After Earnings?</li><li>What is MarketRank™? How to Use it</li><li>Caterpillar Stock Could Top $650 by Year’s End</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkVHTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkVHTg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Regeneron Pharmaceuticals Right Now?</h2><p>Before you consider Regeneron Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.</p><p>While Regeneron Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

REGN

<p>K.J. Harrison & Partners Inc acquired a new stake in Regeneron Pharmaceuticals, purchasing 2,001 shares valued at approximately $1.05 million in Q2. Other institutional investors also increased their stakes. Regeneron reported strong quarterly earnings, exceeding estimates with $11.83 EPS and $3.75 billion in revenue. The company declared a quarterly dividend of $0.88 per share, with a yield of 0.5%. Analysts have varied ratings on the stock, with price targets ranging from $678 to $865.</p>

K.J. Harrison & Partners Inc Buys New Shares in Regeneron Pharmaceuticals, Inc. $REGN